Germany has secured new antibody-based corona drugs.
Health Minister Spahn confirmed the purchase.
Karl Lauterbach (SPD) praised the investment.
The federal government has bought new Corona * drugs for 400 million euros
Health Minister Jens Spahn confirmed the purchase.
(see first report)
There are two substances from US manufacturers.
They are not yet approved in the EU.
(see update from January 24th, 8:08 pm)
Update from January 24th, 8:08 p.m.:
Health Minister
Jens Spahn
has raised hopes with the purchase of corona drugs (see first report).
In the meantime, more details about the treatment method that
is said to have helped
Donald Trump
are known.
The US FDA has already approved the drugs through an emergency procedure.
An assessment by the European authorities is still pending.
Corona antibody drug: Karl Lauterbach (SPD) praises Spahn's approach
The preparations can still be used in clinics.
The
Federal Ministry of Health (BMG) informed the dpa at the request of the dpa that the
application is based on an
individual risk-benefit assessment by the treating physicians
.
FDP health expert Andrew Ullman points out the need for further investigations.
The data situation is thin.
"If Spahn wants to approach the matter professionally, he has no choice but to test the drug as part of a study approval at university clinics."
According to BMG, two different monoclonal antibody-containing drugs were purchased from US manufacturers:
The antibody
Bamlanivimab
from Eli Lilly
and the simultaneously administered antibodies
casirivimab and imdevimab from
the manufacturer Regeneron
However, the
effect of the substances has
not yet been
finally proven
.
"According to the available studies, the medication could
possibly
help to limit the amount of virus in the body and thus have a positive influence on the course of the disease," a ministry spokesman explained the current state of research.
SPD health expert Karl Lauterbach
praised Spahn's approach.
The study situation indicates a
positive influence of
the medication, Lauterbach told the partner newspapers of the Neue Berliner Redaktionsgesellschaft (Monday edition).
“Because of the high cost of these drugs, the clinics would probably not have bought this supply.
So I welcome the action. "
Corona funds: Spahn announces purchase of new Covid drug
First report from January 24th, 9:58 am:
Berlin - The
corona
numbers in
Germany
are
slowly
falling
- probably thanks to the
lockdown
.
However, there is still great concern.
The new
mutations * of
the virus in
particular
recently ensured that the federal and state governments extended the applicable measures until mid-February - for the time being.
At the same time, the vaccination against corona is only starting slowly.
There is still too little vaccine * available.
Exactly at this point in time there is now a message that gives hope:
Germany has secured a new corona drug.
Health Minister
Jens Spahn has
now
confirmed
this to
Bild am Sonntag
.
Accordingly, it is the agent is a novel
drug to antibody
-
based
.
“
From next week, the monoclonal antibodies will be used in Germany as the first country in the EU.
Initially in university clinics, ”said Spahn about
BamS
.
In total, the federal government has bought 200,000 cans for 400 million euros.
Corona agent based on antibodies acts "like a passive vaccination"
"They work like a passive vaccination,"
said Spahn about the drug.
Accordingly, the antibody drug can especially help in the treatment of high-risk patients.
If they are administered in the early stages of an illness, the agent could help prevent a severe course of Covid, Spahn continued.
A similar corona agent probably also helped Donald Trump
According to media reports, the then US President
Donald Trump * was also
treated with this type of antibody after his corona infection.
Trump received the REGN-COV2 antibody cocktail from the US company Regeneron at the beginning of October.
The active ingredient of REGN-COV2 is a combination of two specially developed
antibodies
that bind to the so-called spike protein of the coronavirus and can thus deform its structure.
This is to prevent the coronavirus from attacking human cells.
According to Regeneron, the combination of two different antibodies should prevent the Sars-COV2 virus from mutating.
(rjs / af / dpa) * merkur.de is part of the nationwide Ippen digital editorial network.
List of rubric lists: © Matthias Balk / dpa